Revolution Medicines review

The short version

For forty years, scientists called RAS “undruggable”. This family of proteins drives most pancreatic cancers, yet no medicine could block it broadly. Revolution Medicines, founded in 2014, did just that. Its pill Rasonque (daraxonrasib) is the first broad RAS drug ever approved, and in its Phase 3 trial it nearly doubled survival in a cancer with few options (company results).

The latest FDA decision: approved

On 26 August 2026 the FDA approved Rasonque for adults with pancreatic cancer that has spread and who have had earlier treatment or cannot receive strong chemotherapy, with or without an identified RAS mutation (Revolution Medicines). It came just weeks after filing, thanks to a priority voucher. Because the approval was widely expected, the shares rose only about 5% around the news, as our FDA Decision Calendar shows.

What it makes

Most targeted drugs attack one specific mutation. Rasonque works on the “ON” form of RAS across many mutations, which is why it needs no test before use. In the RASolute 302 trial, patients lived a median 13.2 months vs 6.7 months on chemotherapy, a 60% lower risk of death. Serious treatment-related side effects were less common than on chemotherapy, mainly rash (14%) and mouth sores (12%). One death from lung inflammation was linked to the drug.

More than 2,000 patients had already received the drug through an early access programme before the approval. The company is now testing it in earlier pancreatic cancer and lung cancer, and it has two sister drugs for specific mutations: zoldonrasib (G12D) and elironrasib (G12C).

Is it really new?

Yes, this is a genuine first. Earlier RAS drugs from Amgen and Bristol Myers Squibb hit only the G12C form, which is rare in pancreatic cancer. No other drug of this kind is approved for that disease.

The competition

Rasonque’s first competitor is chemotherapy, which it clearly beat. In lung cancer the field is more crowded: Lumakras and Krazati are already approved for G12C tumours, and Eli Lilly’s olomorasib is in trials. More than a dozen broad RAS drugs are in development, several from China, but Revolution has a head start of years.

Money

Revolution held $3.9 billion of cash on 30 June 2026, after raising $2.2 billion in April, and up to $1.5 billion more is available from Royalty Pharma if milestones are met (Q2 2026 results). It lost $644.4 million in Q2, including a $151 million non-cash charge, and expects $2.1–2.2 billion of expenses in 2026. The list price is about $40,000 a month, about $480,000 a year, and some doctors have criticised it (CBC). Q3 results, the first with Rasonque sales, are still to come.

Risks

• High expectations. The company is worth about $40 billion before reporting a full quarter of sales.
• Price pressure. A price this high invites pushback from insurers, governments and doctors.
• Short treatment time. Patients with advanced pancreatic cancer take a drug for months, not years, which limits sales per patient until it moves to earlier disease.
• Resistance. Tumours can learn to escape RAS drugs, which is why combinations matter.

Our take

Revolution Medicines has delivered one of the biggest advances ever in pancreatic cancer. The science is no longer the main question for its first drug; the questions now are how fast it sells and how far it can spread into earlier disease and lung cancer. At this price the stock needs the 2027 lung results to go well.